Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Erlotinib in Combination With Cetuximab

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Erlotinib
Drug: Cetuximab

First Posted Date: 2009-05-08

Last Posted Date: 2015-07-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 65

Registration Number: NCT00895362

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Erlotinib in Combination With Dasatinib

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Erlotinib Hydrochloride
Drug: Dasatinib

First Posted Date: 2009-05-08

Last Posted Date: 2015-07-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 65

Registration Number: NCT00895128

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Caregiver Assessments of the Quality of Home Hospice Care

Terminated

Conditions: Advanced Cancer

Interventions: Behavioral: Phone Interview/Questionnaire

First Posted Date: 2009-05-07

Last Posted Date: 2020-10-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 74

Registration Number: NCT00895024

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

PR1 Vaccination in Myelodysplastic Syndrome (MDS)

Phase 2

Terminated

Conditions: Leukemia
Myelodysplastic Syndrome

Interventions: Biological: PR-1 vaccine

First Posted Date: 2009-05-06

Last Posted Date: 2012-07-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT00893997

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Acupuncture for Chemo-Induced Peripheral Neuropathy

Phase 2

Completed

Conditions: Myeloma
Lymphoma
Peripheral Neuropathy

Interventions: Other: Acupuncture

First Posted Date: 2009-05-01

Last Posted Date: 2016-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00891618

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide (CTX)
Drug: Vincristine
Drug: Doxorubicin
Drug: Decadron
Drug: G-CSF
Drug: Methotrexate (MTX)
Drug: Ara-C
Drug: Pegaspargase

First Posted Date: 2009-04-30

Last Posted Date: 2012-02-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 90

Registration Number: NCT00890656

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)

Phase 3

Completed

Conditions: Leukemia
AML
MDS

Interventions: Drug: Azacitidine

First Posted Date: 2009-04-23

Last Posted Date: 2020-01-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 187

Registration Number: NCT00887068

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Comparison of Endobronchial Ultrasound-Guided Biopsy Using Fine Needle Aspiration Versus Fine Needle Capillary Sampling

Not Applicable

Completed

Conditions: Lymphadenopathy

Interventions: Procedure: Lymph Node Needle Tissue Collections

First Posted Date: 2009-04-23

Last Posted Date: 2016-02-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT00886847

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

Phase 2

Completed

Conditions: Brain Cancer
Pediatric Cancers

Interventions: Drug: Bevacizumab
Drug: Lapatinib

First Posted Date: 2009-04-20

Last Posted Date: 2020-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00883688

Locations: 🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States

and more 3 locations

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Decitabine
Drug: Gemtuzumab ozogamicin

First Posted Date: 2009-04-16

Last Posted Date: 2013-09-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 43

Registration Number: NCT00882102

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy